### **Overview** Gland Pharma Limited, headquartered in Hyderabad, India, is one of the world’s leading manufacturers of **generic and complex sterile injectables**, with a strategic expansion into **biologics and biosimilars CDMO (Contract Development and Manufacturing Organization)** services. Founded in 1978, the company has evolved from a contract manufacturer into a globally diversified, vertically integrated pharmaceutical enterprise with operations in over **60 countries**, including the U.S., Europe, Canada, Australia, and select emerging markets. Gland operates primarily under a **B2B-focused business model**, serving global pharmaceutical partners through IP-led marketing, technology transfer, and contract manufacturing, complemented by a **targeted B2C presence in India**. The company is majority-owned by **Fosun International (74% stake)**, which has contributed to enhanced global reach, particularly in China. --- ### **Strategic Pillars and Growth Strategy (as of Nov 2025)** Gland Pharma’s long-term growth strategy is anchored on four interconnected pillars: 1. **Geographic Expansion**: Strengthening presence in core markets (U.S., Europe, Canada, Australia) while expanding in high-growth ROW (Rest of the World) geographies such as Saudi Arabia, Brazil, Thailand, Mexico, Chile, Colombia, and China. 2. **Portfolio Diversification**: Shifting from low-value, high-volume generics to **high-value, complex injectables** and **biologics CDMO**. 3. **Strategic Collaborations & In-Licensing**: Pursuing co-development, in-licensing, and M&A opportunities to accelerate innovation and market access. 4. **Global Integration**: Fully integrating Cenexi (acquired 2023) to build a European manufacturing and CDMO platform, reinforcing its status as a global injectables leader. --- ### **Core Business Segments** #### **1. Complex Injectables & Generic Portfolio** - **Product Pipeline**: - **19 complex injectables in development**, targeting a **$6.5–$9.0 billion total addressable market (TAM)**. - To date, **9 regulatory filings completed, 6 launched**, and **3 more expected to gain approval soon**. - Eribulin (launched May 2024) is the first major commercialized complex product, serving as a reference for future launches. - **Regulatory Momentum**: - **371 ANDA filings in the U.S.** (as of Jul 2025), with **318 approved and 53 pending**. - Ongoing regulatory activity: 9 ANDA approvals in Q1 FY26 alone. - **Therapeutic Focus**: Oncology, ophthalmics, CNS disorders, pain management, immunology, chemo adjuvants, endocrinology, blood derivatives, and radiocontrast agents. #### **2. Ready-to-Use (RTU) Infusion Bags** - A key differentiator in the U.S. market: - **14 approved RTU infusion bags** in the U.S., representing an **addressable market of ~$530–620 million**. - **20 RTU filings total**, with **14 approved, 1 filed in Q1 FY26, and 10 more in development** (total U.S. market TAM: **~$760 million**). - RTUs are designed to meet growing demand for patient-friendly, differentiated delivery systems. #### **3. Co-Development & 505(b)(2) Portfolio** - **15 co-developed formulations under development** through partnership with **MAIA Pharmaceuticals** and other specialty firms: - **7 under the 505(b)(2) pathway**, targeting faster approvals and lifecycle extension for modified drugs. - **8 under ANDA** (generic approvals). - Commercialization expected from **FY2026–2027**, with key products focusing on **immunology, pain management, endocrinology, and fertility**. #### **4. Biologics & Biosimilars CDMO Expansion** - **Strategic partnerships** driving entry into the **biologics CDMO** space: - **Dr. Reddy’s Laboratories**: Strategic collaboration utilizing Gland’s **Genome Valley biologics facility** in Hyderabad; first revenue expected in **FY26**. - **Shanghai Henlius Biotech**: Non-binding term sheet signed to make Gland a **secondary manufacturing site** for key biosimilars. - **Capacity Expansion**: - Adding **15,000L of stainless-steel bioreactor capacity**, increasing total biologics capacity from **8,000L to 23,000L**. - **GLP-1 Launch**: - Launched **Liraglutide (a GLP-1 agonist)** in the UK and Australia via a partner model. - Two commercial contracts secured; plans to scale **cartridge and pen production to 140 million units by 2026**. --- ### **Manufacturing & Operational Excellence** #### **Global Manufacturing Network** - **11 sites** (7 in India, 4 in Europe via Cenexi acquisition): - **4 formulation plants in India** (Dundigal, Pashamylaram, Penems). - **3 API facilities in India** (Visakhapatnam, Hyderabad). - **4 Cenexi sites** in France (Hérouville, Osny) and Belgium (Braine-l'Alleud), FDA and EMA-approved, specializing in sterile and complex formulations. - **32 flexible production lines** across facilities with annual formulation capacity of ~1 billion units. - **Full vertical integration** for APIs—critical for cost control, quality, and regulatory stability. #### **Key Manufacturing Initiatives (Nov 2025)** - **Braine-l'Alleud (Belgium)**: - Two new **lyophilizers** being installed and expected to be qualified by **end of 2025**. - Engineering underway for a **new vial line under isolator** with automated loading/unloading to enhance sterile manufacturing. - **Pashamylaram (India)**: - Dedicated suites for **hormonal products, suspensions, microspheres, and combi-vials**. - **Cenexi Revitalization**: - €60M+ capex planned over 3 years to upgrade infrastructure, improve efficiency, and target **high-teens operating margins**. --- ### **Financial & Market Performance (as of Aug 2025)** #### **Revenue & Market Share** - **United States** remains the **primary revenue engine**, contributing **₹30,387 million (approx. $370M)** in the current period (~54% of group revenue). - **Core markets (U.S., Europe, Canada, Australia, New Zealand)**: 78% of total revenue in FY24. - **Rest of the World (ROW)**: - Grew 63% YoY in FY24 due to Cenexi integration. - Contributing **~20–21% of total revenue**, with potential to **double within 3–5 years**. - Major gains in Saudi Arabia (a $50–55M tender secured) and Latin America. #### **Product Launches & Regulatory Momentum** - **FY25**: Launched **31 new molecules in the U.S.**, reinforcing leadership. - **Q1 FY26**: - 9 new product launches. - 9 ANDA approvals; 1 new filing and 1 RTU filing. - **U.S. RTU Bags**: 14 approved, 6 more in pipeline—positioning Gland as a leader in differentiated injectables. --- ### **R&D and Innovation Landscape** - **Centralized R&D in Hyderabad**, supported by site-specific teams (~250–350 scientists). - Focus areas: - **Complex molecules**: Low Molecular Weight Heparins (LMWH), peptides, corticosteroids, cytotoxics. - **Advanced drug delivery**: Pen injectors, cartridges, dual/triple-chamber bags, lyophilization, microspheres. - **Analytical innovation**: Proprietary tools to characterize heparins, glycosaminoglycans, and protein conjugates. - **R&D Models**: In-house development, co-development, in-licensing, and tech transfers. - **Near-term R&D pipeline**: - **~40 new ANDAs** targeting **$1.25B market** (1–3 year horizon). - **71 in-house ANDA pipeline** with **$5.71B TAM**. - Focus on **first-to-file (FTF)**, **NCE-1s**, and **505(b)(2)** for higher margins. --- ### **Business Model & Revenue Streams** | **B2B Model** | **Description** | **Revenue Mechanism** | |---------------|------------------|------------------------| | **Own Filing (IP-led)** | Gland owns ANDA/IP, partners distribute. | License/milestone payments, profit-sharing, royalties | | **Partner Filing** | Partner owns ANDA, uses Gland’s IP and manufacturing. | Milestone payments, per-unit royalty | | **Tech Transfer** | Customer transfers tech to Gland. | Upfront fee + per-unit royalty | | **CMO (Direct Sales)** | Contract manufacturing under loan/license. | Fixed per-unit pricing | - **B2C in India**: Direct sales via ~66-person team, covering **4,000+ hospitals**, nursing homes, and government institutions. - **Cost Advantage**: High-volume orders improve production efficiency and reduce SG&A spend. --- ### **Key Strategic Acquisitions & Collaborations** 1. **Cenexi (2023 Acquisition)** - **Cost**: €114.26M equity + €79.46M debt refinancing. - **Objective**: Establish European CDMO footprint; access niche technologies (ophthalmic gels, hormones, needleless injectors). - **Impact**: Expanded EU client base, especially in biologics; enabled U.S. market supply of controlled substances via European manufacturing. 2. **Vitane Biologics (2020)** - Enhanced **biotech drug substance manufacturing** capabilities in Hyderabad.